tolazamide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antihyperglycaemics | 2694 | 1156-19-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.50 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 0.28 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 53.63 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| July 18, 1966 | FDA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A10BB05 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Sulfonylureas |
| FDA CS | M0020795 | Sulfonylurea Compounds |
| CHEBI has role | CHEBI:35526 | antidiabetic |
| FDA EPC | N0000175608 | Sulfonylurea |
| MeSH PA | D007004 | Hypoglycemic Agents |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Diabetes mellitus type 2 | indication | 44054006 | DOID:9352 |
| Alcoholism | contraindication | 7200002 | |
| Asthenia | contraindication | 13791008 | |
| Uremia | contraindication | 44730006 | DOID:4676 |
| Acidosis | contraindication | 51387008 | |
| Hepatic porphyria | contraindication | 55056006 | DOID:3133 |
| Hypopituitarism | contraindication | 74728003 | DOID:9406 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Hypoglycemic disorder | contraindication | 237630007 | |
| Primary adrenocortical insufficiency | contraindication | 373662000 | |
| Surgical procedure | contraindication | 387713003 | |
| Traumatic injury | contraindication | 417746004 | |
| Fever greater than 100.4 Fahrenheit | contraindication | 426000000 | |
| Prolonged-Severe Nausea and Vomiting | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 5.97 | acidic |
| pKa2 | 3.54 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Sulfonylurea receptor 1, Kir6.2 | Ion channel | BLOCKER | CHEMBL | CHEMBL | |||||
| Arachidonate 15-lipoxygenase | Enzyme | IC50 | 5.29 | DRUG MATRIX |
External reference:
| ID | Source |
|---|---|
| 4017829 | VUID |
| N0000146187 | NUI |
| D00379 | KEGG_DRUG |
| 4017829 | VANDF |
| C0040372 | UMLSCUI |
| CHEBI:9613 | CHEBI |
| CHEMBL817 | ChEMBL_ID |
| DB00839 | DRUGBANK_ID |
| D014042 | MESH_DESCRIPTOR_UI |
| 5503 | PUBCHEM_CID |
| 6847 | IUPHAR_LIGAND_ID |
| 1296 | INN_ID |
| 9LT1BRO48Q | UNII |
| 10633 | RXNORM |
| 1119 | MMSL |
| 1138 | MMSL |
| 5593 | MMSL |
| d00393 | MMSL |
| 000911 | NDDF |
| 34393009 | SNOMEDCT_US |
| 387186009 | SNOMEDCT_US |
Pharmaceutical products:
None